Rockefeller Capital Management’s ADC Therapeutics ADCT Stock Holding History

Rockefeller Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$462	Sell	431 -1,057	-71%	-$3.08K	﹤0.01%	4605
2026 Q1	$5.58K	Buy	1,488 +1,057	+245%	+$4.17K	﹤0.01%	4207
2025 Q4	$1.52K	Buy	431 +266	+161%	+$1.08K	﹤0.01%	4378
2025 Q3	$660	Buy	+165	New	+$520	﹤0.01%	4235
2023 Q2	–	Sell	-24,701	Closed	-$48K	–	1807
2023 Q1	$48K	Hold	24,701	–	–	﹤0.01%	1927
2022 Q4	$94K	Sell	24,701 -270	-1%	-$1.08K	﹤0.01%	2055
2022 Q3	$120K	Sell	24,971 -89	-0.4%	-$645	﹤0.01%	1887
2022 Q2	$198K	Buy	25,060 +89	+0.4%	+$842	﹤0.01%	1637
2022 Q1	$365K	Hold	24,971	–	–	﹤0.01%	1444
2021 Q4	$503K	Hold	24,971	–	–	﹤0.01%	1311
2021 Q3	$677K	Hold	24,971	–	–	﹤0.01%	1151
2021 Q2	$607K	Sell	24,971 -54,426	-69%	-$1.26M	﹤0.01%	1112
2021 Q1	$1.94M	Hold	79,397	–	–	0.01%	585
2020 Q4	$2.54M	Buy	+79,397	New	+$2.6M	0.02%	459

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rockefeller Capital Management's ADCT Position: Q2 2026 in Review

Rockefeller Capital Management reduced its ADC Therapeutics (ADCT) stake by 71% in Q2 2026, selling an estimated $3.08K and leaving 431 shares worth $462. The position accounts for ﹤0.01% of the portfolio, ranked #4605.

Rockefeller Capital Management first reported a position in ADCT in Q4 2020 and has held it in 14 quarters since. The position peaked at $2.54M in Q4 2020. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Rockefeller Capital Management held 431 shares of ADC Therapeutics worth $462 as of Q2 2026.
Rockefeller Capital Management sold 1,057 ADC Therapeutics shares in Q2 2026, an estimated $3.08K.
ADC Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4605 holding.
Rockefeller Capital Management first reported a position in ADC Therapeutics in Q4 2020 and has held it in 14 quarters since.
Rockefeller Capital Management's ADC Therapeutics position peaked at $2.54M in Q4 2020.
113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.